Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by LPL Financial LLC

LPL Financial LLC raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 5.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 644,324 shares of the biopharmaceutical company’s stock after purchasing an additional 33,283 shares during the quarter. LPL Financial LLC owned 0.05% of Gilead Sciences worth $44,368,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in GILD. E Fund Management Co. Ltd. purchased a new position in shares of Gilead Sciences in the 1st quarter valued at approximately $1,201,000. Quilter Plc grew its stake in shares of Gilead Sciences by 4.2% in the 1st quarter. Quilter Plc now owns 67,083 shares of the biopharmaceutical company’s stock valued at $4,336,000 after purchasing an additional 2,711 shares during the last quarter. Cresset Asset Management LLC boosted its stake in shares of Gilead Sciences by 13.1% in the first quarter. Cresset Asset Management LLC now owns 23,143 shares of the biopharmaceutical company’s stock valued at $1,495,000 after buying an additional 2,679 shares in the last quarter. Cidel Asset Management Inc. boosted its stake in shares of Gilead Sciences by 2.2% in the first quarter. Cidel Asset Management Inc. now owns 11,333 shares of the biopharmaceutical company’s stock valued at $732,000 after buying an additional 241 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Gilead Sciences by 3.0% in the first quarter. Geode Capital Management LLC now owns 20,671,306 shares of the biopharmaceutical company’s stock valued at $1,332,764,000 after buying an additional 592,386 shares in the last quarter. Institutional investors own 78.04% of the company’s stock.

A number of research firms recently weighed in on GILD. Morgan Stanley lifted their price target on Gilead Sciences from $83.00 to $84.00 and gave the company an “overweight” rating in a research note on Tuesday. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “hold” rating and set a $72.00 price target on the stock in a research note on Tuesday, August 10th. Royal Bank of Canada restated a “buy” rating and issued a C$84.00 price target on shares of Gilead Sciences in a research note on Monday, August 23rd. SVB Leerink lifted their price target on Gilead Sciences from $74.00 to $77.00 and gave the company an “outperform” rating in a research note on Friday, July 30th. Finally, BMO Capital Markets lifted their price target on Gilead Sciences from $67.00 to $72.00 and gave the company a “market perform” rating in a research note on Friday, July 30th. Eight analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $105.72.

In related news, CAO Diane E. Wilfong sold 13,610 shares of the company’s stock in a transaction on Tuesday, August 17th. The stock was sold at an average price of $72.50, for a total value of $986,725.00. Following the completion of the transaction, the chief accounting officer now directly owns 30,179 shares in the company, valued at $2,187,977.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.12% of the company’s stock.

NASDAQ GILD opened at $67.63 on Thursday. Gilead Sciences, Inc. has a fifty-two week low of $56.56 and a fifty-two week high of $73.34. The stock has a market cap of $84.80 billion, a price-to-earnings ratio of 16.50, a price-to-earnings-growth ratio of 0.63 and a beta of 0.39. The business has a fifty day moving average of $70.59 and a 200-day moving average of $68.42. The company has a quick ratio of 1.19, a current ratio of 1.36 and a debt-to-equity ratio of 1.42.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, July 29th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.76 by $0.11. Gilead Sciences had a return on equity of 55.94% and a net margin of 19.38%. The company had revenue of $6.22 billion during the quarter, compared to analysts’ expectations of $6.15 billion. During the same period in the previous year, the firm posted $1.11 earnings per share. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.15 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 29th. Investors of record on Wednesday, September 15th were paid a $0.71 dividend. The ex-dividend date was Tuesday, September 14th. This represents a $2.84 annualized dividend and a yield of 4.20%. Gilead Sciences’s payout ratio is currently 40.06%.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

See Also: Is it better to buy a fund with a higher or lower NAV?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.